[
  {
    "ts": null,
    "headline": "Watch These Johnson & Johnson Price Levels After Stock's Post-Earnings Pop",
    "summary": "Johnson & Johnson shares fell slightly Thursday after soaring yesterday amid investor optimism about the company's better-than-expected earnings and full-year outlook. Watch these crucial chart levels.",
    "url": "https://finnhub.io/api/news?id=91ea01ce39cecb38a9e0d75fea830fe147fb78dc0c9b4b42eece8bc849b7d3c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752793442,
      "headline": "Watch These Johnson & Johnson Price Levels After Stock's Post-Earnings Pop",
      "id": 136005446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson shares fell slightly Thursday after soaring yesterday amid investor optimism about the company's better-than-expected earnings and full-year outlook. Watch these crucial chart levels.",
      "url": "https://finnhub.io/api/news?id=91ea01ce39cecb38a9e0d75fea830fe147fb78dc0c9b4b42eece8bc849b7d3c0"
    }
  },
  {
    "ts": null,
    "headline": "ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook",
    "summary": "IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.",
    "url": "https://finnhub.io/api/news?id=709bd1d9a5b954a0b7927c2a7910079ea43152098f38211703c8741cd1392835",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752764400,
      "headline": "ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook",
      "id": 135996826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.",
      "url": "https://finnhub.io/api/news?id=709bd1d9a5b954a0b7927c2a7910079ea43152098f38211703c8741cd1392835"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Jul 17, 2025",
    "summary": "Companies in The News Are: JNJ,GS,PGR,FHN",
    "url": "https://finnhub.io/api/news?id=22fb686163a3f22268d2e0803129e523a80913337f7614e6d9096f0ba9e150b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752759720,
      "headline": "Company News for Jul 17, 2025",
      "id": 135993134,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Companies in The News Are: JNJ,GS,PGR,FHN",
      "url": "https://finnhub.io/api/news?id=22fb686163a3f22268d2e0803129e523a80913337f7614e6d9096f0ba9e150b9"
    }
  },
  {
    "ts": null,
    "headline": "Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down",
    "summary": "NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.",
    "url": "https://finnhub.io/api/news?id=0f7d5fa5472aae28672a4aff9c36f2bc6fe446bd7fc8807bb88c997c0b5615b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752759600,
      "headline": "Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down",
      "id": 135993135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.",
      "url": "https://finnhub.io/api/news?id=0f7d5fa5472aae28672a4aff9c36f2bc6fe446bd7fc8807bb88c997c0b5615b0"
    }
  },
  {
    "ts": null,
    "headline": "Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility",
    "summary": "WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company’s cell therapy manufacturing operations. This state-of-the-art facility aligns with Tevogen’s strategic goals of accelerating clinical development while mainta",
    "url": "https://finnhub.io/api/news?id=77c4ecd488f146df487db178b86c7ad8611108826f867f2a320f015cbf142612",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752758100,
      "headline": "Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility",
      "id": 135993136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company’s cell therapy manufacturing operations. This state-of-the-art facility aligns with Tevogen’s strategic goals of accelerating clinical development while mainta",
      "url": "https://finnhub.io/api/news?id=77c4ecd488f146df487db178b86c7ad8611108826f867f2a320f015cbf142612"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "url": "https://finnhub.io/api/news?id=75de218b016d1aa1d661e0f20f738f5444500f8d9969d8032ab7f365b65b7e5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752757802,
      "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
      "id": 135993137,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
      "url": "https://finnhub.io/api/news?id=75de218b016d1aa1d661e0f20f738f5444500f8d9969d8032ab7f365b65b7e5e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: The Worst Is Baked In",
    "summary": "J&J's strong financials, dividend growth, and undervaluation make it a top buy for long-term investors, despite legal challenges.",
    "url": "https://finnhub.io/api/news?id=aeb227b1e7b04cb8f76c69300199adcf907817f884072a49ed7c8a49c6de6e4f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752756026,
      "headline": "Johnson & Johnson: The Worst Is Baked In",
      "id": 135992818,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "J&J's strong financials, dividend growth, and undervaluation make it a top buy for long-term investors, despite legal challenges.",
      "url": "https://finnhub.io/api/news?id=aeb227b1e7b04cb8f76c69300199adcf907817f884072a49ed7c8a49c6de6e4f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine releasing system, for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.",
    "url": "https://finnhub.io/api/news?id=1d312bbd31c67d6decca80fef6ba96c58f14364ba6e8aed64e0422897d396e2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752753600,
      "headline": "Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer",
      "id": 135993138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine releasing system, for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.",
      "url": "https://finnhub.io/api/news?id=1d312bbd31c67d6decca80fef6ba96c58f14364ba6e8aed64e0422897d396e2c"
    }
  },
  {
    "ts": null,
    "headline": "Abbott profit forecast falls short, ramps up US investing amid tariff pressure",
    "summary": "(Reuters) -Abbott on Thursday forecast third-quarter profit below Wall Street expectations and estimated about $200 million in annual tariff costs.  The medical device maker's shares slid 8%, even as it announced a new plant in the U.S. to mitigate the hit from President Donald Trump's sweeping duties on trading partners.  Speaking on a post-earnings call, Chief Financial Officer Phil Boudreau said the impact of tariffs will likely be felt in the second half of the year, as the company works its way through its inventory.",
    "url": "https://finnhub.io/api/news?id=a4de5337344f875174f84c5e34924642ed1bcd17f5d60310550a257ed5d5cef4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752752029,
      "headline": "Abbott profit forecast falls short, ramps up US investing amid tariff pressure",
      "id": 135993139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Reuters) -Abbott on Thursday forecast third-quarter profit below Wall Street expectations and estimated about $200 million in annual tariff costs.  The medical device maker's shares slid 8%, even as it announced a new plant in the U.S. to mitigate the hit from President Donald Trump's sweeping duties on trading partners.  Speaking on a post-earnings call, Chief Financial Officer Phil Boudreau said the impact of tariffs will likely be felt in the second half of the year, as the company works its way through its inventory.",
      "url": "https://finnhub.io/api/news?id=a4de5337344f875174f84c5e34924642ed1bcd17f5d60310550a257ed5d5cef4"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income",
    "summary": "Johnson & Johnson continues to generate plenty of free cash flow to cover its dividend.  The healthcare giant also maintains an elite balance sheet.  Johnson & Johnson (NYSE: JNJ) has been an extremely reliable dividend stock for decades.",
    "url": "https://finnhub.io/api/news?id=296c3822a08b7313cdef69f1cb7b130f814343c7aa7a1d36fad99cfd1aa863e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752746700,
      "headline": "Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income",
      "id": 135993140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson continues to generate plenty of free cash flow to cover its dividend.  The healthcare giant also maintains an elite balance sheet.  Johnson & Johnson (NYSE: JNJ) has been an extremely reliable dividend stock for decades.",
      "url": "https://finnhub.io/api/news?id=296c3822a08b7313cdef69f1cb7b130f814343c7aa7a1d36fad99cfd1aa863e7"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson a Good Dividend Stock to Buy Now?",
    "summary": "Johnson & Johnson reported second-quarter results on July 16.  Sales of pharmaceuticals have been muted due to a loss of market exclusivity for Stelara.  A strong medical technology segment and an expanding pharmaceutical business could keep pushing the dividend higher despite patent expirations.",
    "url": "https://finnhub.io/api/news?id=e1e1d15179b35f01ff7ac9761b53d3d6e1a0603d78468f7ec927cebfccb6c6f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752741420,
      "headline": "Is Johnson & Johnson a Good Dividend Stock to Buy Now?",
      "id": 135993141,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson reported second-quarter results on July 16.  Sales of pharmaceuticals have been muted due to a loss of market exclusivity for Stelara.  A strong medical technology segment and an expanding pharmaceutical business could keep pushing the dividend higher despite patent expirations.",
      "url": "https://finnhub.io/api/news?id=e1e1d15179b35f01ff7ac9761b53d3d6e1a0603d78468f7ec927cebfccb6c6f8"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Gets Speedy FDA Review of TAR-200 in Bladder Cancer",
    "summary": "Johnson & Johnson Gets Speedy FDA Review of TAR-200 in Bladder Cancer",
    "url": "https://finnhub.io/api/news?id=b056acbab7ec119814e5dc38de3c3910d7176728ad35b2b802f7053809c42295",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752740400,
      "headline": "Johnson & Johnson Gets Speedy FDA Review of TAR-200 in Bladder Cancer",
      "id": 136002059,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson Gets Speedy FDA Review of TAR-200 in Bladder Cancer",
      "url": "https://finnhub.io/api/news?id=b056acbab7ec119814e5dc38de3c3910d7176728ad35b2b802f7053809c42295"
    }
  },
  {
    "ts": null,
    "headline": "J&J accelerates past Stelara’s fall with better-than-expected portfolio growth",
    "summary": "Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.",
    "url": "https://finnhub.io/api/news?id=21d8aef451c86cba4575a5fe1d1db9c11765cd3a37be9260c6f7d9497ea8ed14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752739200,
      "headline": "J&J accelerates past Stelara’s fall with better-than-expected portfolio growth",
      "id": 135993142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.",
      "url": "https://finnhub.io/api/news?id=21d8aef451c86cba4575a5fe1d1db9c11765cd3a37be9260c6f7d9497ea8ed14"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Q2 2025 Earnings Call Highlights: Strong Sales Growth Amid Challenges",
    "summary": "Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance despite facing headwinds from loss of exclusivity and market pressures.",
    "url": "https://finnhub.io/api/news?id=cc414939d00b62226d7acea5c9a16d8124cc8eb653fe1bb258c8fe9ffc7bf56c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752735775,
      "headline": "Johnson & Johnson (JNJ) Q2 2025 Earnings Call Highlights: Strong Sales Growth Amid Challenges",
      "id": 135993143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance despite facing headwinds from loss of exclusivity and market pressures.",
      "url": "https://finnhub.io/api/news?id=cc414939d00b62226d7acea5c9a16d8124cc8eb653fe1bb258c8fe9ffc7bf56c"
    }
  }
]